Search Results for "Benzodiazepine Multiple Sclerosis"

19:20 EST 30th November 2015 | BioPortfolio

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Systemic Sclerosis

Amyotrophic lateral sclerosis ALS

Diffuse mesangial sclerosis

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Matching News

Benzodiazepines in Primary Care: Danger

Appropriate treatment of anxiety is of paramount importance in the primary care setting. Family practice providers are in a position to best understand each patient's background, resources and challen...

Genentech has positive results for patients with multiple sclerosis

Genentech’s phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) show positive results

Specific subset of b-cell responsible for Multiple Sclerosis disease activity identified.

An estimated 100,000 Canadians live with multiple sclerosis; there is currently no cure for the disease.  Modern scientific understanding has considered multiple sclerosis (MS) to be a disease contr...

Novartis Buys Rights to Multiple Sclerosis Drug from GlaxoSmithKline

Novartis is acquiring all the remaining rights to GlaxoSmithKline’s (GSK) multiple sclerosis (MS) drug, Ofatumumab. A fully human monoclonal antibody which targets the CD20 molecule, Ofatumumab ...

New finding will help target multiple sclerosis immune response

Researchers have made another important step in the progress towards being able to block the development of multiple sclerosis (MS) and other autoimmune diseases.

Multiple Sclerosis Treatment Market Value to Reach $20 Billion by 2024

The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 1.5%, according to ...

Latest research on cognitive dysfunction in Multiple Sclerosis patients an eye opener

In a paper published in Nature Reviews Neurology, researchers at Monash University have revealed that eye movement measures can help identify the presence and progression of Multiple Sclerosis (MS).

Roche's ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis

Roche today announced data from three positive, pivotal Phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).

Matching PubMed Articles

Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.

To date, there are no available factors to predict the outcome after multiple sclerosis relapse.

Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database.

Data are limited for mortality and comorbidities in patients with multiple sclerosis (MS).

Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis.

Cognitive deficits are common in multiple sclerosis. Most previous studies investigating the imaging substrate of cognitive deficits in multiple sclerosis included patients with relatively short disea...

Season of birth and multiple sclerosis in Tunisia.

Recent studies on date of birth of multiple sclerosis (MS) patients showed an association between month of birth and the risk of developing MS. This association has not been investigated in an African...

Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.

In search of the missing heritability in multiple sclerosis (MS), additional approaches adding to the genetic discoveries of large genome-wide association studies are warranted.

Search Whole site using Google


Advertisement Advertisement